Novavax NVAX Stock Surges on H1N1 Swine Flu Goal

August 5, 2009 - Shares of Novavax, Inc. (NVAX) are surging Up 22% to $5.65 this morning as the company is reporting substantial news on their swine flu vaccine. There is not much resistance until the $7's while support is at $5

NVAX News 8/5/09

NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone

cGMP quality material produced in 11 weeks from strain availability

Novavax, Inc. (Nasdaq: NVAX) announced today it has manufactured a virus-like particle (VLP) vaccine candidate against the H1N1 pandemic influenza virus under current good-manufacturing practices (cGMP) at its new vaccine manufacturing facility in Rockville, MD. This milestone was accomplished in only 11 weeks after receiving the gene sequence for the H1N1 strain from the U.S. Centers for Disease Control. The Company was able to reach this manufacturing goal by employing proprietary, novel production technology which is not dependent on growing influenza virus in eggs. Chicken eggs are used to produce almost all of the world's influenza vaccine supply. In addition, Novavax has produced essential reagents for measuring vaccine potency. The Company also has plans to produce additional batches of the pandemic H1N1 VLP vaccine to support human clinical studies and stands ready to assist with additional public health needs in the US as well as foreign countries. Full Article

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free